Aegera Closes $15 Million Round of Financing
Aegera Therapeutics said this week that it has closed a $15 million Series C round of financing.
The financing, said the company, was led by VenGrowth Advanced Life Sciences Fund and included new and existing investors. Proceeds of the financing will be used to support the clinical development of Aegera’s lead product candidates, including a phase I antisense cancer drug.
FDA Grants Pharmion’s Demethylating MDS Drug Priority Review